Entity

Time filter

Source Type

Houston, TX, United States

The Texas Heart Institute is a not-for-profit cardiology and heart surgery center located within the Texas Medical Center in Houston, Texas. Founded in 1962 by Dr. Denton A. Cooley, its original charter stated its purpose was “the study and treatment of diseases of the heart and blood vessels. Today, the Institute’s mission is to reduce the devastating toll of cardiovascular disease through innovative programs in research, education, and improved patient care. The Texas Heart Institute and its clinical partner, St. Luke's Episcopal Hospital, have become one of the nation's largest cardiovascular centers. Its 160-member professional staff have performed more than 100,000 open heart operations, 200,000 cardiac catheterizations, and 1,000 heart transplants. In 2010, in its annual survey of “America's Best Hospitals,” U.S. News & World Report ranked the Texas Heart Institute at St. Luke's Episcopal Hospital number 4 in the United States for heart care, making this its 20th consecutive year as one of the top 10 heart centers in the country. Wikipedia.


Patent
Texas Heart Institute | Date: 2015-06-10

An introducer includes a sheath for introducing a catheter into a blood vessel at an insertion site and a plurality of electrodes on the sheath. The introducer also includes an impedance assessment unit connected to the electrodes. The impedance assessment unit includes a power source and a wireless transceiver and is configured to inject one of a predetermined current or voltage across a first pair of electrodes and to measure the other of the current or voltage across a second pair of electrodes. The impedance assessment unit also is configured to perform at least one: wirelessly transmit current and voltage values to an external apparatus for detection of a bleed, and compute an impedance based on the current and voltage and wirelessly transmit the computed impedance to the external apparatus for detection of the bleed.


A method of enhancing binding of cells to an integrin-binding ligand comprises treating integrin-expressing cells in vitro with an agonist of integrin, wherein the integrin is selected from the group consisting of 41, 51, 47, v3 and L2, and contacting the treated cells with an integrin-binding ligand; integrin agonist compounds having the general formula I; methods of treating integrin-expressing cells with such agonists to enhance binding; and therapeutic methods comprising administering agonist-treated cells or agonist compounds to a mammal.


A method of enhancing binding of cells to an integrin-binding ligand comprises treating integrin-expressing cells in vitro with an agonist of integrin, wherein the integrin is selected from the group consisting of 41, 51, 47, v3 and L2, and contacting the treated cells with an integrin-binding ligand; integrin agonist compounds having the general formula I; methods of treating integrin-expressing cells with such agonists to enhance binding; and therapeutic methods comprising administering agonist-treated cells or agonist compounds to a mammal.


An isolated peptidic fragment of apolipoprotein E comprises at least 3 contiguous amino acids, Including glycosylated threonine 194, threonine 289, serine 94, or serine 76 of SEQ ID NO.: 1, or any combination of those. An antibody capable of binding to the isolated peptidic fragment. A method of detecting a naturally-occurring circulating atherogenic low-density lipoprotein in a plasma sample from an individual, comprising qualitatively and/or quantitatively detecting in a low-density lipoprotein that binds to the antibody. A method of assessing an individuals risk of ischemic heart disease and/or atherosclerosis comprises quantifying in a plasma sample from the individual an amount of apolipoprotein E comprising glycosylated threonine 194, threonine 289, serine 94 or serine 76 of SEQ ID NO.: 1, or any combination of those.


A method of enhancing binding of cells to an integrin-binding ligand comprises treating integrin-expressing cells in vitro with an agonist of integrin, wherein the integrin is selected from the group consisting of 41, 51, 47, v3 and L2, and contacting the treated cells with an integrin-binding ligand; integrin agonist compounds having the general formula I; methods of treating integrin-expressing cells with such agonists to enhance binding; and therapeutic methods comprising administering agonist-treated cells or agonist compounds to a mammal.

Discover hidden collaborations